Though the small subset of dMMR PDAC tumors respond well to PD-L1 inhibitors, immunomodulatory antibodies have not shown the same caliber of widespread clinical benefit in PDAC when compared to other solid tumors such as non-small cell lung cancer (NSCLC) [7,73]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.